Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2008

01-03-2008 | Breast Oncology

Breast Conservation Therapy: Multiple Reexcisions or Subcutaneous and Nipple-Sparing Mastectomy?

Authors: E. Lykoudis, MD, N. Xeropotamos, MD, D. Ziogas, MD, M. Fatouros, MD

Published in: Annals of Surgical Oncology | Issue 3/2008

Login to get access

Excerpt

Currently, with excellent survival and good cure rates for early-stage breast cancer,1 efforts have been focused on the improvement of cosmetic results, satisfaction level, and quality of life of women with breast cancer after surgery. After randomized evidence for equivalent overall survival between breast conservation therapy (BCT) and mastectomy, the quality of life of more women with localized breast cancer will benefit from BCT. However, local recurrence rates ranging 10% and 20% at 10 years after BCT urgently suggest the need for careful pretreatment selection of patients for BCT who are at low risk of local recurrence.2 …
Literature
1.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66PubMedCrossRef
2.
Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 2003;10:718–21PubMedCrossRef
3.
O’ Sullivan MJ, Li T, Freedman G, Morrow M. The effect of multiple reexcisions on the risk of local recurrence after breast conserving surgery. Ann Surg Oncol (in press)
4.
Bollet MA, Sigal-Zafrani B, Mazeau V. Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first. Radiother Oncol 2007;82:272–80. Erratum in: Radiother Oncol 2007;83:215PubMedCrossRef
5.
Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;366:2087–106PubMed
6.
Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 2005;5:737–45PubMedCrossRef
7.
8.
Roukos DH, Hottenrott C, Encke A, Baltogiannis G, Casioumis D. Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 1994;3:115–25PubMedCrossRef
9.
Kappas AM, Fatouros M, Roukos DH. Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 2004;11:727–30PubMedCrossRef
10.
Roukos DH. Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 1998;80:16–24PubMed
11.
Roukos DH, Kappas AM. Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 2002;81:59–62PubMedCrossRef
12.
Roukos DH, Hottenrott C, Lorenz M, Koutsogiorgascouchell S. A critical-evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach – an analysis of early results and long-term survival. J Cancer Res Clin 1990;116:307–313 CrossRef
13.
Roukos DH, Lorenz M, Karakostas K, Paraschou P, Batsis C, Kappas AM. Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 2001;84:1602–9PubMedCrossRef
14.
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for respectable gastroesophageal cancer. N Engl J Med 2006;355:11–20PubMedCrossRef
15.
Briasoulis E, Fatouros M, Roukos DH. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 2007;14:2691–5PubMed
16.
Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradio therapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–30PubMedCrossRef
17.
Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 2002;9:220–1 PubMedCrossRef
18.
Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005;2:98–107PubMedCrossRef
19.
Roukos DH. Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 1999;6:46–56PubMedCrossRef
20.
Metcalfe KA, Semple JL, Narod SA. Time to reconsider sub-cutaneous mastectomy for breast-cancer prevention? Lancet Oncol 2005;6:431–4PubMedCrossRef
21.
Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of hereditary breast ovarian cancer. Ann Surg Oncol 2007. doi:10.​1245/​s10434-007-9612-4
22.
Sacchini V, Pinotti JA, Barros AC, et al. Nipplesparing mastectomy for breast cancer and risk reduction: oncologic or technical problem? J Am Coll Surg 2006;203:704–14PubMedCrossRef
23.
Roukos DH. Prognosis of Breast Cancer in Carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007;357:1555–6PubMedCrossRef
24.
Roukos DH. Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007;357:115–23CrossRef
25.
Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 2002;9:607–9PubMed
26.
Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 2002;9:941–3PubMed
27.
Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 2004;11:1030–4PubMedCrossRef
28.
Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007;6:308–12PubMedCrossRef
29.
Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 2007;4:578–90PubMedCrossRef
Metadata
Title
Breast Conservation Therapy: Multiple Reexcisions or Subcutaneous and Nipple-Sparing Mastectomy?
Authors
E. Lykoudis, MD
N. Xeropotamos, MD
D. Ziogas, MD
M. Fatouros, MD
Publication date
01-03-2008
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 3/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9686-z

Other articles of this Issue 3/2008

Annals of Surgical Oncology 3/2008 Go to the issue

Gastrointestinal Oncology

Racial Disparities in Esophageal Cancer Treatment and Outcomes

Breast Oncology

In Reply

Gastrointestinal Oncology

Surgical Margins during Hepatic Surgery for Colorectal Liver Metastases: Complete Resection not Millimeters Defines Outcome

Healthcare Policy and Outcomes

The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United States

Hepatic and Pancreatic Tumors

Laparoscopic Liver Surgery for Patients with Hepatocellular Carcinoma

Gastrointestinal Oncology

Comparison Between the Minimum Margin Defined on Preoperative Imaging and the Final Surgical Margin After Hepatectomy for Cancer: How to Manage It?